1. Home
  2. IMMP vs NREF Comparison

IMMP vs NREF Comparison

Compare IMMP & NREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • NREF
  • Stock Information
  • Founded
  • IMMP 1987
  • NREF 2019
  • Country
  • IMMP Australia
  • NREF United States
  • Employees
  • IMMP N/A
  • NREF N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • NREF Real Estate Investment Trusts
  • Sector
  • IMMP Health Care
  • NREF Real Estate
  • Exchange
  • IMMP Nasdaq
  • NREF Nasdaq
  • Market Cap
  • IMMP 211.1M
  • NREF 242.2M
  • IPO Year
  • IMMP N/A
  • NREF 2020
  • Fundamental
  • Price
  • IMMP $1.86
  • NREF $14.36
  • Analyst Decision
  • IMMP Buy
  • NREF Hold
  • Analyst Count
  • IMMP 2
  • NREF 4
  • Target Price
  • IMMP $8.50
  • NREF $14.25
  • AVG Volume (30 Days)
  • IMMP 648.0K
  • NREF 45.2K
  • Earning Date
  • IMMP 05-16-2025
  • NREF 05-01-2025
  • Dividend Yield
  • IMMP N/A
  • NREF 13.95%
  • EPS Growth
  • IMMP N/A
  • NREF N/A
  • EPS
  • IMMP N/A
  • NREF 2.69
  • Revenue
  • IMMP $3,019,249.00
  • NREF $108,951,000.00
  • Revenue This Year
  • IMMP $11.25
  • NREF $24.31
  • Revenue Next Year
  • IMMP $10.22
  • NREF $5.86
  • P/E Ratio
  • IMMP N/A
  • NREF $5.32
  • Revenue Growth
  • IMMP 24.11
  • NREF 325.97
  • 52 Week Low
  • IMMP $1.32
  • NREF $12.14
  • 52 Week High
  • IMMP $3.34
  • NREF $18.09
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 53.43
  • NREF 50.84
  • Support Level
  • IMMP $1.44
  • NREF $14.07
  • Resistance Level
  • IMMP $2.71
  • NREF $14.66
  • Average True Range (ATR)
  • IMMP 0.17
  • NREF 0.51
  • MACD
  • IMMP 0.05
  • NREF 0.12
  • Stochastic Oscillator
  • IMMP 29.75
  • NREF 68.98

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.

Share on Social Networks: